High resolution melting for mutation scanning of TP53 exons 5-8

被引:112
|
作者
Krypuy, Michael
Ahmed, Ahmed Ashour
Etemadmoghadam, Dariush
Hyland, Sarah J.
deFazio, Anna
Fox, Stephen B.
Brenton, James D.
Bowtell, David D.
Dobrovic, Alexander
机构
[1] Peter MacCallum Canc Ctr, Dept Pathol, Mol Pathol Res & Dev Lab, Melbourne, Vic 8006, Australia
[2] Li Ka Shing Ctr, Canc Res UK Cambridge Res Inst, Funct Genom Drug Resistance Lab, Cambridge CB2 0RE, England
[3] Univ Melbourne, Dept Biochem & Mol Biol, Parkville, Vic 3010, Australia
[4] Peter MacCallum Canc Ctr, Ian Potter Ctr Genom & Predict Med, Melbourne, Vic 8006, Australia
[5] Univ Cambridge, MRC, Res Ctr, Cambridge CB2 2XZ, England
[6] Univ Sydney, Westmead Hosp, Westmead Millennium Inst, Westmead Inst Canc Res, Westmead, NSW 2145, Australia
[7] Univ Melbourne, Dept Pathol, Parkville, Vic 3010, Australia
关键词
D O I
10.1186/1471-2407-7-168
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: p53 is commonly inactivated by mutations in the DNA-binding domain in a wide range of cancers. As mutant p53 often influences response to therapy, effective and rapid methods to scan for mutations in TP53 are likely to be of clinical value. We therefore evaluated the use of high resolution melting (HRM) as a rapid mutation scanning tool for TP53 in tumour samples. Methods: We designed PCR amplicons for HRM mutation scanning of TP53 exons 5 to 8 and tested them with DNA from cell lines hemizygous or homozygous for known mutations. We assessed the sensitivity of each PCR amplicon using dilutions of cell line DNA in normal wild-type DNA. We then performed a blinded assessment on ovarian tumour DNA samples that had been previously sequenced for mutations in TP53 to assess the sensitivity and positive predictive value of the HRM technique. We also performed HRM analysis on breast tumour DNA samples with unknown TP53 mutation status. Results: One cell line mutation was not readily observed when exon 5 was amplified. As exon 5 contained multiple melting domains, we divided the exon into two amplicons for further screening. Sequence changes were also introduced into some of the primers to improve the melting characteristics of the amplicon. Aberrant HRM curves indicative of TP53 mutations were observed for each of the samples in the ovarian tumour DNA panel. Comparison of the HRM results with the sequencing results revealed that each mutation was detected by HRM in the correct exon. For the breast tumour panel, we detected seven aberrant melt profiles by HRM and subsequent sequencing confirmed the presence of these and no other mutations in the predicted exons. Conclusion: HRM is an effective technique for simple and rapid scanning of TP53 mutations that can markedly reduce the amount of sequencing required in mutational studies of TP53.
引用
收藏
页数:13
相关论文
共 50 条
  • [41] Gestational choriocarcinoma associated with a germline TP53 mutation
    Anne-Claire Brehin
    Sophie Patrier-Sallebert
    Gaëlle Bougeard
    Gwendoline Side-Pfennig
    Francisco Llamas Gutierrez
    Aude Lamy
    Elodie Colasse
    Christine Kandel-Aznar
    Capucine Delnatte
    Eric Vuillemin
    Sophie Sadot-Lebouvier
    Sylvie Odent
    Jean-Christophe Sabourin
    François Golfier
    Thierry Frebourg
    Familial Cancer, 2018, 17 : 113 - 117
  • [42] TP53 Mutation and Survival in Chronic Lymphocytic Leukemia
    Zenz, Thorsten
    Eichhorst, Barbara
    Busch, Raymonde
    Denzel, Tina
    Haebe, Sonja
    Winkler, Dirk
    Buehler, Andreas
    Edelmann, Jennifer
    Bergmann, Manuela
    Hopfinger, Georg
    Hensel, Manfred
    Hallek, Michael
    Doehner, Hartmut
    Stilgenbauer, Stephan
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (29) : 4473 - 4479
  • [43] Gestational choriocarcinoma associated with a germline TP53 mutation
    Brehin, Anne-Claire
    Patrier-Sallebert, Sophie
    Bougeard, Gaelle
    Side-Pfennig, Gwendoline
    Gutierrez, Francisco Llamas
    Lamy, Aude
    Colasse, Elodie
    Kandel-Aznar, Christine
    Delnatte, Capucine
    Vuillemin, Eric
    Sadot-Lebouvier, Sophie
    Odent, Sylvie
    Sabourin, Jean-Christophe
    Golfier, Francois
    Frebourg, Thierry
    FAMILIAL CANCER, 2018, 17 (01) : 113 - 117
  • [44] TP53 mutation analysis in chronic lymphocytic leukaemia
    Fesus Viktoria
    Marosvari Dora
    Kajtar Bela
    Kiraly Peter Attila
    Demeter Judit
    Gurbity Palfi Timea
    Egyed Miklos
    Plander Mark
    Farkas Peter
    Matrai Zoltan
    Matolcsy Andras
    Bodor Csaba
    ORVOSI HETILAP, 2017, 158 (06) : 220 - 228
  • [45] Germline mutation in the TP53 gene in uveal melanoma
    Nikola Hajkova
    Jan Hojny
    Kristyna Nemejcova
    Pavel Dundr
    Jan Ulrych
    Katerina Jirsova
    Johana Glezgova
    Ivana Ticha
    Scientific Reports, 8
  • [46] Germline mutation in the TP53 gene in uveal melanoma
    Hajkova, Nikola
    Hojny, Jan
    Nemejcova, Kristyna
    Dundr, Pavel
    Ulrych, Jan
    Jirsova, Katerina
    Glezgova, Johana
    Ticha, Ivana
    SCIENTIFIC REPORTS, 2018, 8
  • [47] TP53 mutation spectrum in lung cancers and mutagenic signature of components of tobacco smoke:: lessons from the IARC TP53 mutation database
    Hainaut, P
    Olivier, M
    Pfeifer, GP
    MUTAGENESIS, 2001, 16 (06) : 551 - 553
  • [48] The relationship of TP53 R72P polymorphism to disease outcome and TP53 mutation in myelodysplastic syndromes
    McGraw, K. L.
    Zhang, L. M.
    Rollison, D. E.
    Basiorka, A. A.
    Fulp, W.
    Rawal, B.
    Jerez, A.
    Billingsley, D. L.
    Lin, H-Y
    Kurtin, S. E.
    Yoder, S.
    Zhang, Y.
    Guinta, K.
    Mallo, M.
    Sole, F.
    Calasanz, M. J.
    Cervera, J.
    Such, E.
    Gonzalez, T.
    Nevill, T. J.
    Haferlach, T.
    Smith, A. E.
    Kulasekararaj, A.
    Mufti, G.
    Karsan, A.
    Maciejewski, J. P.
    Sokol, L.
    Epling-Burnette, P. K.
    Wei, S.
    List, A. F.
    BLOOD CANCER JOURNAL, 2015, 5 : e291 - e291
  • [49] The relationship of TP53 R72P polymorphism to disease outcome and TP53 mutation in myelodysplastic syndromes
    K L McGraw
    L M Zhang
    D E Rollison
    A A Basiorka
    W Fulp
    B Rawal
    A Jerez
    D L Billingsley
    H-Y Lin
    S E Kurtin
    S Yoder
    Y Zhang
    K Guinta
    M Mallo
    F Solé
    M J Calasanz
    J Cervera
    E Such
    T González
    T J Nevill
    T Haferlach
    A E Smith
    A Kulasekararaj
    G Mufti
    A Karsan
    J P Maciejewski
    L Sokol
    P K Epling-Burnette
    S Wei
    A F List
    Blood Cancer Journal, 2015, 5 : e291 - e291
  • [50] TP53 immunohistochemistry correlates with TP53 mutation status and clearance in decitabine-treated patients with myeloid malignancies
    Ruzinova, Marianna B.
    Lee, Yi-Shan
    Duncavage, Eric J.
    Welch, John S.
    HAEMATOLOGICA, 2019, 104 (08) : E345 - E348